Study of alpha-synuclein brain disease in patients and healthy people
Part of Brain & nervous system clinical trials.
This study follows people with a primary alpha-synuclein diagnosis and compares them with healthy controls. It aims to better understand this condition and may help researchers design better future tests and treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor’s clinical diagnosis of primary alpha-synuclein disease (alpha-synucleinopathy)
- If you are a healthy control, you must be a person without this disease
- You must not have secondary alpha-synuclein disease that can’t be ruled out
- You must not have other neurological (brain/nervous system) disorders
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines changes in alpha-synuclein, a protein linked to Parkinson's, to better understand how the disease progresses. It may help researchers learn more about Parkinson's and improve future care.
This study looks for changes in a protein called alpha-synuclein in people who may be in the early “prodromal” stage before Parkinson’s symptoms fully appear. It may help researchers find early markers and understand who is more likely to develop Parkinson’s disease.
This study collects health information from people with neurodegenerative diseases, some family members, and healthy controls to help researchers better understand these conditions. It may help future diagnosis and research, and participation may include noninvasive checks and other procedures depending on your situation.
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
This study looks at how a protein called alpha-synuclein spreads in Parkinson's disease by checking blood and brain scans. It aims to understand why some people develop Parkinson's and to find clues that could lead to better treatments.
This study looks at how your symptoms, brain imaging (MRI), and genetic factors relate to neurodegenerative conditions. It may help researchers better understand what causes these illnesses and how to classify them.
Hear when a new α-synucleinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.